Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Policymakers Under Industry Pressure To 'Neuter' SPC Waiver Plan

Executive Summary

“Vested interests” are pressuring EU policymakers to water down further European Commission plans for an exemption intended to allow generic and biosimilar firms to manufacture their versions of products for export while SPCs are still in effect, claims the industry sector body Medicines for Europe.

You may also be interested in...



EU SPC Waiver Move Puts Originator And Generic/Biosimilar Firms At Odds

A European Commission legislative proposal to change the EU’s rules on supplementary protection certificates and allow for the production of versions of patent-protected medicines for sale outside the EU has been welcomed by the generics and biosimilars industry – albeit with caveats – but criticized by the originator industry as an attack on intellectual property that could hit investment in Europe.

COVID-19 Vaccine Contracts Rarely Disclose Price & Delivery Details

At current rates, not enough coronavirus vaccines will be manufactured in 2021 or even 2022 to meet global demand or achieve global population immunity, according to a new dataset that monitors vaccine supply agreements around the world.

Coronavirus Notebook: Africa Backs IP Waiver Proposal, CEOs To Face EU Parliamentary Hearing On Vaccine Supply

Sanofi and GSK have restarted their Phase II vaccine study, Australia is allowing public advertising of coronavirus vaccines, and Sputnik V has landed in Mexico.

Topics

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel